BioCryst Pharmaceuticals Inc
BCRX7.320USD
+0.070+0.97%
收盤 10/31, 16:00（美東）報價延遲15分鐘
1.54B總市值
虧損本益比TTM
關於 BioCryst Pharmaceuticals Inc 公司
BioCryst Pharmaceuticals, Inc. 是一家專注於改善補體介導疾病和其他罕見疾病患者生活的生物技術公司。該公司利用其在設計方面的專業知識開發一流的口服小分子和蛋白質療法，以治療難治疾病。其上市產品包括用於預防遺傳性血管性水腫 (HAE) 發作的口服每日一次 ORLADEYO 和用於治療美國急性無併發症流感的 RAPIVAB（帕拉米韋注射液）。其其他產品和候選產品包括 BCX10013、RAPIACTA（帕拉米韋注射液）、PERAMIFLU（帕拉米韋注射液）和早期發現項目。BCX10013 是一種強效且特異的 D 因子抑制劑。RAPIACTA 專注於無併發症的季節性流感。RAPIVAB（帕拉米韋注射液）在美國獲批用於治療 6 個月及以上患者的急性無併發症流感。
BioCryst Pharmaceuticals Inc簡介
公司代碼BCRX
公司名稱BioCryst Pharmaceuticals Inc
上市日期Mar 04, 1994
CEOMr. Charles K. Gayer
員工數量580
證券類型Ordinary Share
年結日Mar 04
公司地址4505 Emperor Blvd Ste 200
城市DURHAM
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編27703-8457
電話19198591302
網址https://www.biocryst.com/
公司代碼BCRX
上市日期Mar 04, 1994
CEOMr. Charles K. Gayer
BioCryst Pharmaceuticals Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
90.44K
+0.75%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
70.87K
+21.41%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
64.27K
+24.14%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
41.01K
+1.68%
Dr. Jill C. Milne, Ph.D.
Dr. Jill C. Milne, Ph.D.
Director
Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
90.44K
+0.75%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2023
暫無數據
地區USD
名稱
營收
佔比
United States (Country)
140.34M
85.91%
Outside of U.S.
16.50M
10.10%
Other
6.52M
3.99%
業務
地區
暫無數據
股東統計
更新時間: 8月16日 週六
更新時間: 8月16日 週六
持股股東
股東類型
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.74%
BlackRock Institutional Trust Company, N.A.
8.09%
Deerfield Management Company, L.P.
5.78%
Two Sigma Investments, LP
4.05%
State Street Investment Management (US)
4.04%
其他
68.31%
持股股東
持股股東
佔比
The Vanguard Group, Inc.
9.74%
BlackRock Institutional Trust Company, N.A.
8.09%
Deerfield Management Company, L.P.
5.78%
Two Sigma Investments, LP
4.05%
State Street Investment Management (US)
4.04%
其他
68.31%
股東類型
持股股東
佔比
Investment Advisor
36.25%
Investment Advisor/Hedge Fund
28.94%
Hedge Fund
25.79%
Research Firm
6.43%
Individual Investor
1.19%
Pension Fund
1.00%
Bank and Trust
0.45%
Family Office
0.06%
Sovereign Wealth Fund
0.05%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
553
208.53M
99.05%
+5.29M
2025Q2
551
184.03M
87.67%
-16.63M
2025Q1
560
182.40M
87.18%
-20.97M
2024Q4
556
172.66M
82.64%
-37.08M
2024Q3
554
179.19M
86.60%
-34.24M
2024Q2
532
180.82M
87.59%
-35.90M
2024Q1
546
187.78M
91.10%
-27.21M
2023Q4
549
183.67M
89.35%
-28.91M
2023Q3
542
183.90M
96.89%
-26.67M
2023Q2
545
181.25M
95.65%
-20.15M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
The Vanguard Group, Inc.
20.50M
9.77%
-1.12M
-5.16%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
17.04M
8.12%
-849.42K
-4.75%
Jun 30, 2025
Deerfield Management Company, L.P.
12.17M
5.8%
+7.48M
+159.36%
Sep 12, 2025
Two Sigma Investments, LP
8.52M
4.06%
+3.25M
+61.72%
Jun 30, 2025
State Street Investment Management (US)
8.51M
4.05%
+691.99K
+8.86%
Jun 30, 2025
Kynam Capital Management LP
8.46M
4.03%
-464.78K
-5.21%
Jun 30, 2025
UBS Financial Services, Inc.
5.61M
2.67%
+3.21M
+133.63%
Jun 30, 2025
Geode Capital Management, L.L.C.
5.05M
2.41%
+93.97K
+1.89%
Jun 30, 2025
Alkeon Capital Management LLC
4.76M
2.27%
-1.24M
-20.69%
Jun 30, 2025
Avoro Capital Advisors LLC
4.50M
2.14%
-4.20M
-48.28%
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
iShares Genomics Immunology and Healthcare ETF
2.75%
Invesco Biotechnology & Genome ETF
2.37%
Virtus LifeSci Biotech Products ETF
1.22%
ALPS Medical Breakthroughs ETF
0.95%
SPDR S&P Biotech ETF
0.72%
First Trust Small Cap Growth AlphaDEX Fund
0.53%
Invesco NASDAQ Future Gen 200 ETF
0.44%
Direxion Daily S&P Biotech Bull 3X Shares
0.41%
AAM Sawgrass US Small Cap Quality Growth ETF
0.38%
First Trust Small Cap Core Alphadex Fund
0.24%
查看更多
iShares Genomics Immunology and Healthcare ETF
佔比2.75%
Invesco Biotechnology & Genome ETF
佔比2.37%
Virtus LifeSci Biotech Products ETF
佔比1.22%
ALPS Medical Breakthroughs ETF
佔比0.95%
SPDR S&P Biotech ETF
佔比0.72%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.53%
Invesco NASDAQ Future Gen 200 ETF
佔比0.44%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.41%
AAM Sawgrass US Small Cap Quality Growth ETF
佔比0.38%
First Trust Small Cap Core Alphadex Fund
佔比0.24%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
